HC Wainwright Has Bullish Estimate for Pharvaris Q3 Earnings

Pharvaris N.V. (NASDAQ:PHVS) – Research analysts at HC Wainwright raised their Q3 2025 EPS estimates for Pharvaris in a report issued on Tuesday, November 11th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.68) per share for the quarter, up from their previous estimate of ($0.69). HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Pharvaris’ Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($3.28) EPS, Q2 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($3.38) EPS and FY2027 earnings at ($2.64) EPS.

Other equities research analysts have also issued research reports about the company. Bank of America raised Pharvaris from an “underperform” rating to a “neutral” rating and boosted their target price for the company from $16.00 to $27.00 in a research note on Thursday, October 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th. Zacks Research raised shares of Pharvaris from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. Finally, JMP Securities cut their price target on shares of Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $37.17.

Pharvaris Stock Up 7.0%

NASDAQ PHVS opened at $25.81 on Thursday. The company has a 50-day simple moving average of $23.14 and a two-hundred day simple moving average of $20.58. Pharvaris has a 12-month low of $11.51 and a 12-month high of $26.33. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -7.68 and a beta of -2.78.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.08.

Institutional Investors Weigh In On Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Pharvaris during the 2nd quarter valued at about $57,000. JPMorgan Chase & Co. lifted its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Pharvaris during the 3rd quarter valued at approximately $75,000. Legal & General Group Plc grew its holdings in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the period. Finally, California State Teachers Retirement System grew its holdings in shares of Pharvaris by 9.8% during the 2nd quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock worth $247,000 after acquiring an additional 1,257 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.